Giving people more vitality and quality of life at every stage of life is what drives us at mse Pharmazeutika.
Every single day.
About mse
-
mse Pharmazeutika GmbH is a medium-sized, family-owned company founded in 1992 and based in Bad Homburg v. d. Höhe. We conduct research and development in the field of mitochondrial medicine and are a provider of high-quality, mitotropic substances (also known as Mitoceuticals®) for the individual protection of mitochondria.
-
At the heart of the MitoMed concept, developed by company founder Dr. Enzmann, is ubiquinol / ubiquinone Q10 as a key substance in the mitochondria, the "power plants of our cells." Our products can be individually dosed and combined, similar to a modular system.
Milestones of mse Pharmazeutika GmbH
Founding of mse Pharmazeutika GmbH by Dr. Franz Enzmann and his wife Uta Enzmann in Bad Homburg
Development of the MitoMed concept with its specific active ingredients (Mitoceuticals®) for the protection and activation of mitochondria, the "power plants of our cells"
Publication of the first clinical study with an mse Q10 product:
- “The increase in endurance capacity of endurance athletes correlates with the rise in plasma Q10 levels after Q10 supplementation”, G. P. Littarru, Energy and Defense
Expansion of activities across the entire German-speaking region (DACH)
Market launch of SanoMit® Q10, the first liquid ubiquinone Q10 product; Q10 is present in ultra-small droplets and can be absorbed by the body faster and approximately 4 times more effectively than conventional Q10 in powder capsules
Publication of clinical studies:
- “Supplementary administration of guttaquinone in inflammatory periodontal diseases”, K. Erler et al., GZM, 2002
- “Coenzyme Q10 combined with mild hypothermia after cardiac arrest“, M. S. Damian et al., Circulation, 2004
- “Influence of coenzyme Q10 and cerivastatin on the flow-mediated vasodilation“, A. Kuettner et al., Int. J Cardiol., 2005
- “Efficacy of coenzyme Q10 in migraine prophylaxis“, P. S. Sándor et al., Int. J Cardiol., 2005
- “Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in parkinson disease“, A. Storch et al., Arch. Neurol., 2007
- “Short-term effects of coenzyme Q10 in progressive supranuclear palsy“, A. Stamelou et al., Mov. Disord., 2008
mse continues to grow: Moving to Nehringstraße in Bad Homburg
Market launch of QuinoMit Q10® fluid; it contains ubiquinol, the active form of Q10, in ultra-small droplets and is absorbed twice as well as SanoMit® Q10.
Expansion of activities into Poland through the distribution partner "Mito-Pharma"
Cooperation with Albstadt-Sigmaringen University on "Use of QuinoMit Q10® fluid for skin aging", Prof. Dr. J. Bergemann
Cooperation with the Institute for Neurophysiology at the University of Cologne on the “Use of QuinoMit Q10® fluid in cardiac stem cell research”, Prof. Dr. Dr. J. Hescheler
Expansion of activities into Taiwan through the distribution partner "Reformhaus"
Expansion of activities into Sweden through the sales partner "Tiwa Care"
Use of QuinoMit Q10® fluid in intensive care for patients with traumatic brain injury
Product launch of medicinal supplements (AEGS®) for complementary nutritional support when taking cholesterol-lowering medication (statins), antidiabetics (metformin), or oral contraceptives
Publication of the clinical study „Accelerated Regeneration of ATP Level after Irradiation in Human Skin Fibroblasts by Coenzyme Q10“, D. Schniertshauer et al., Photochemistry and Photobiology
IHK award "Excellent Technology Transfer" in cooperation with Albstadt-Sigmaringen University, Prof. Dr. J. Bergemann
Poster Prize of the World Mitochondria Society at the 7th World Congress Targeting Mitochondria 2016
Publication on “Observational study on skin care for atopic dermatitis – MythoSkin® Care Cream / Liposome Cream by mse Pharmazeutika”, Aesthetic Dermatology
Inclusion of our 2004 clinical study „Coenzyme Q10 combined with mild hypothermia after cardiac arrest“ in the American Academy of Neurology guidelines
Publication of the clinical study "Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients", C.-H. Yen et al., British Journal of Nutrition
How we work
Evidence-based research
Before a Mitoceutical® is created, there is science. Our research department clinically examines the efficacy of every active ingredient, because our goal is to establish mitochondrial medicine as an evidence-based paradigm in modern medicine.
Nano-formulation & bioavailability
What is the best active ingredient worth if it doesn't reach its target? With our nano-formulation technology – made famous by the world's first liquid Q10 – we maximize bioavailability at the cellular level. Here, nano means no compromises, but rather precision at the highest scientific level.
Bottling & Production
From formulation directly into production: Our filling lines operate to the highest standards – whether for liquids, capsules, or tablets. Every step is designed to maintain the quality of the formulation through to the finished product.
Galenical optimization & dosage forms
The best effect is achieved through the right form. Our galenic experts develop dosage forms that optimally release the active ingredient – from sustained-release vitamin C and liquid mitoceuticals to capsules, tablets, and cosmetic & dental applications.
Quality Assurance & Labeling
Every batch is subject to comprehensive testing at our facility. From laboratory analysis to final labeling, we ensure that our products meet the highest quality standards.
Personalized customer support
For us, work does not end in the laboratory. Our customer support is our top priority. We provide personal, peer-to-peer support to our professional partners and customers. Because trust is the foundation of every good therapy decision.
Get to know us. The mse team introduces itself:
